GlobeNewsWire
17 Aug 2026, 10:48 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
An FDA advisory committee voted 9-3 that available evidence does not support the efficacy of Capricor's lead product candidate, Deramiocel, for treating DMD-associated cardiomyopathy. — Negative advisory committee votes are a primary precursor to FDA rejection, severely damaging the commercial viability of a biotech's lead asset.
-0.90The FDA raised concerns regarding post-hoc changes to the statistical analysis plan and primary endpoint calculations for Deramiocel just before the database was unblinded. — Allegations of manipulating statistical plans to achieve favorable results undermine the scientific integrity of clinical data and regulatory trust.
-0.80Capricor Therapeutics is facing a securities fraud class action lawsuit alleging misstatements regarding clinical data integrity and its Biologics License Application. — Legal liabilities and fraud allegations create additional financial risk and reputational damage beyond the clinical failure.
-0.50Continue reading
6 related stories
Search tags
The FDA previously issued a Complete Response Letter stating the Deramiocel application did not meet the statutory requirement for substantial evidence of effectiveness. — A CRL confirms the initial application failed, necessitating more costly and time-consuming clinical trials.
-0.40Which stocks this story touches
The company is facing a securities fraud class action lawsuit following a massive stock drop and FDA concerns regarding the efficacy and data integrity of its lead product candidate.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
2h ago
